Merck Animal Health Supports Rabies Elimination by 2030 on World Rabies Day

Campaign raises awareness about importance of dog vaccination

In recognition of World Rabies Day on September 28, Merck Animal Health, known as MSD Animal Health outside the United States and Canada, a division of Merck & Co., Inc., Kenilworth, N.J., USA (NYSE:MRK), today announced the launch of a global campaign to raise awareness among veterinarians, dog owners and volunteers who are committed to eliminate rabies through ongoing dog vaccination efforts. In partnership with Mission Rabies and Rabies Free Africa, the social media initiative recognizes and celebrates those individuals who are committed to protecting and saving canine as well as human lives, using the hashtag, #ForThemForUs.

"Many of us love and rely on our dogs, who in many cases are not only much-loved family members, but also hard-working companions," said Luke Gamble, BVSc, DVM&S, FRCVS, founder, Mission Rabies. "On this World Rabies Day, we want to recognize the invaluable role dogs play in our lives. When we protect our dogs from rabies, we are also protecting ourselves from this deadly disease. Showcasing those efforts through #ForThemForUs moments is a fitting way to raise awareness about why vaccinating dogs and educating people about preventing rabies matters and saves lives."

Around the world, there are an estimated 900 million dogs i but the majority (75-85%) are not household pets ii . In order to prevent rabies transmission in rabies-endemic areas, at least 70% of the dogs there need to be protected through annual mass-vaccination iii . For over 20 years, Merck Animal Health, through the Afya Program, has been dedicated to rabies prevention and has donated over three million doses of rabies vaccine to help meet the World Health Organization (WHO) "Zero by 2030" goal.

Each year, an estimated 59,000 people die from rabies, with over 99% of cases contracted from a dog bite. Additionally, 40% of those deaths occur in children 15 years and under. This is in part because of low rates of canine vaccination in rabies endemic areas and a lack of awareness about the disease.

"With Merck Animal Health, we have made significant progress on the research needed to design cost-effective and efficient vaccination programs that reduce rates of rabies in both dogs and humans," notes Felix Lankester, DVM, Ph.D., director, Rabies Free Africa, Paul G. Allen School for Global Animal Health, Washington State University. "From scientific research to actual vaccination programs, we are refining the tools we need to prevent rabies. While doing so, we must continue to work together with local governments and healthcare organizations supporting local communities as they continue rabies prevention where it is most needed. This will help us achieve our 2030 rabies elimination goal."

Collaboration must continue among human, animal and environmental health organizations to advance sustainable rabies prevention efforts, including annual mass-vaccination. Through this One Health approach, local, regional, national and global animal health advocates all have a critical role in addressing this public health threat and must work together to keep both dogs and humans healthy.

"Experiencing first-hand the important work of our partners, veterinarians and volunteers was the inspiration behind our campaign, #ForThemForUs," said Ingrid Deuzeman, global marketing director, Companion Animal Vaccines, Merck Animal Health. "We wanted to recognize the global community for their role in eliminating rabies – from the local veterinarian who vaccinates dogs in a veterinary clinic to the door-to-door efforts of volunteers and the Mission Rabies and Rabies Free Africa teams across the African continent and beyond to vaccinate owned and stray dogs. We hope that by everyone sharing their #ForThemForUs moments with the world, these outstanding individuals and not-for-profit organizations will gain even more awareness and support to expand rabies prevention and elimination efforts."

For example, as a commitment to rabies vaccination in Goa, India, there have been no recorded human rabies deaths for two years. "During the COVID-19 pandemic, the Mission Rabies local team remained essential to ensure rabies did not re-emerge in the area. Throughout this period, our team was on-call to respond to any reported rabid dogs. After several positive cases were confirmed, they also quickly launched an emergency rabies vaccination drive to prevent spread," said Gamble.

Veterinarians, dog owners and volunteers are invited to share photos and videos of their inspirational work in keeping dogs rabies-free, using the hashtag, #ForThemForUs.

About Mission Rabies

Mission Rabies was initially founded as an initiative by Worldwide Veterinary Service (WVS), a United Kingdom-based charity group that assists animals. Mission Rabies has a One Health approach driven by research to eliminate dog bite transmitted rabies (a disease that is estimated to kill 59,000 people annually). Launched in September 2013 with a mission to vaccinate 50,000 dogs against rabies across India, Mission Rabies teams have since then vaccinated 1.1 million dogs and educated more than three million children in dog bite prevention in rabies endemic countries. For more information, visit www.missionrabies.com .

About Rabies Free Africa

Rabies Free Africa is empowering countries in east Africa to create self-sustaining programs to eliminate current human rabies deaths and set up surveillance systems to identify future outbreaks for containment. To reach the global goal by 2030, the focus needs to be on decreasing the cost of vaccinating dogs and increasing access to vaccines. Rabies Free Africa continues its work to discover ways to decrease the cost of mass-dog vaccinations and refine country and continent-wide programs that make the best use of limited resources. For more information, visit www.globalhealth.wsu.edu/initiatives/rabies-free-africa/ .

About the Afya Program

The Afya Program comprises a number of rabies control projects supported by Merck Animal Health rabies vaccine donations, including Rabies Free Africa, Mission Rabies and The Sharon Live On Project. These projects have been brought together under the name "Afya," which means "health" in Swahili. The Afya Program is committed to supporting the Zero by 30 Initiative, with the goal of eliminating rabies by 2030. For more information, visit www.afya.org .

About Merck Animal Health

For more than a century, Merck, a leading global biopharmaceutical company, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Merck Animal Health, a division of Merck & Co., Inc., Kenilworth, N.J., USA, is the global animal health business unit of Merck. Through its commitment to The Science of Healthier Animals® , Merck Animal Health offers veterinarians, farmers, pet owners and governments one of the widest ranges of veterinary pharmaceuticals, vaccines and health management solutions and services as well as an extensive suite of digitally connected identification, traceability and monitoring products. Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals and the people who care for them. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.merck-animal-health.com or connect with us on LinkedIn , Facebook , and Twitter at @MerckAH.

i World Atlas. How Many Dogs Are There In The World? Accessed June 15, 2020. https://www.worldatlas.com/articles/how-many-dogs-are-there-in-the-world.html

ii World Atlas. How Many Dogs Are There In The World? Accessed June 15, 2020. https://www.worldatlas.com/articles/how-many-dogs-are-there-in-the-world.html

iii The World Health Organization. Frequently Asked Questions about Rabies for the General Public . Accessed June 15, 2020. https://www.who.int/rabies/Rabies_General_Public_FAQs_Sep2018.pdf?ua=1

Merck
Media Contact:
Michael Close
+ 1 (267) 305-1211
Michael.L.Close@merck.com

News Provided by Business Wire via QuoteMedia

The Conversation (0)
Pill package with up arrow.

Top 3 Canadian Pharma Stocks of 2024

From established players to up-and-coming firms, Canada's pharmaceutical landscape is diverse and dynamic.

Three months into 2024, market watchers are keeping a close eye on pharma companies vying for the next major innovation.

Here the Investing News Network lists the top Canadian pharma stocks trading on the Toronto Stock Exchange (TSX) and the TSX Venture Exchange (TSXV). Companies considered had market caps above C$100 million and were arranged based on year-on-year performance. All data was compiled on April 16, 2024, using TradingView’s stock screener.

Keep reading...Show less

New Novartis Fabhalta® data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy

  • APPLAUSE-IgAN is first and only Phase III study to demonstrate significant proteinuria reduction by targeting the complement system in patients with IgAN 1

  • IgAN is a heterogeneous, progressive, rare kidney disease and is a major cause of chronic kidney disease worldwide 2 ; complement activation is a key driver of glomerular inflammation in IgAN 3,4

  • There is a need for effective, targeted therapies for IgAN 2,5 ; up to 30% of patients with persistent proteinuria (≥1 g/day) may progress to kidney failure within 10 years, requiring maintenance dialysis and/or kidney transplantation 6

  • Novartis continues to advance broad renal portfolio in late-stage development, exploring the potential to slow disease progression and extend dialysis-free life

Novartis today presented results from a pre-specified interim analysis of the Phase III APPLAUSE-IgAN study of Fabhalta ® (iptacopan), an investigational Factor B inhibitor of the alternative complement pathway, in patients with IgA nephropathy (IgAN) 1 . In the analysis, patients treated with Fabhalta achieved a 38.3% (p

Proteinuria reduction is an increasingly recognized surrogate marker correlating with progression to kidney failure and has been used as an endpoint in IgAN clinical trials to support accelerated approvals 7 . The study also showed that Fabhalta was well tolerated with a favorable safety profile consistent with previously reported data 1,8 . Results were presented today during a late-breaking clinical trials session at the World Congress of Nephrology (WCN) in Buenos Aires, Argentina 1 .

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor Protein Degrader ARV-766 for the Treatment of Prostate Cancer

Arvinas to receive a $150 million upfront payment for the license of ARV-766 and the sale of Arvinas' preclinical AR-V7 program, with the potential under the License Agreement for up to $1.01 billion in development, regulatory, and commercial milestones, as well as tiered royalties –

– Novartis to be responsible for worldwide clinical development and commercialization of ARV-766 –

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

New Novartis data show early addition of twice-yearly* Leqvio® following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting

  • V- INITIATE trial demonstrates that early initiation with Leqvio, prior to guideline-recommended ezetimibe, for ASCVD patients unable to achieve LDL-C goal on statin therapy alone led to significant LDL-C reduction vs. clinician-determined usual care (60% vs. 7% respectively) 1
  • A significantly greater proportion of the ASCVD patients receiving Leqvio achieved guideline-recommended LDL-C goal vs. the usual care arm while maintaining adherence to statin treatment 1
  • Results from usual care arm reinforce the urgent need for more aggressive LDL-C lowering in ASCVD patients, 92% of whom did not reach their LDL-C goal with statins alone 1
  • The Leqvio safety profile was consistent with the Phase III clinical studies and long-term open-label extension trials for up to 6 years of treatment 1-4

Novartis today announced new data demonstrating the early addition of twice-yearly* Leqvio ® (inclisiran) to maximally tolerated statin therapy, prior to guideline-recommended ezetimibe, in a real-world setting significantly reduced low-density lipoprotein cholesterol (LDL-C) in patients with atherosclerotic cardiovascular disease (ASCVD), including those with a history of an ASCVD-related event, who could not reach their goal on statin therapy alone 1 . The late-breaking data were presented at the 2024 American College of Cardiology's Annual Scientific Session & Expo and simultaneously published in the Journal of the American College of Cardiology .

"V-INITIATE evaluated a solution to the important challenge seen in clinical practice of too many patients with ASCVD not achieving guideline-recommended LDL-C goal on statins alone and effective non-statin therapies being markedly underutilized," said Michael Koren , M.D., Medical Director and CEO of Jacksonville Center for Clinical Research, and the primary investigator of the study. "Given the urgent need to more aggressively manage LDL-C, the results from V-INITIATE show that when added earlier in the treatment continuum, the structured use of effective non-statin therapies like Leqvio can significantly reduce LDL-C for ASCVD patients who are struggling to reach or maintain their LDL-C goal."

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Cardiol Therapeutics Announces Year-End 2023 Update on Operations

Cardiol Therapeutics Announces Year-End 2023 Update on Operations

Completed patient enrollment in the Phase II MAvERIC-Pilot study evaluating CardiolRx™ in patients with
recurrent pericarditis, with topline results expected in Q2 2024

CardiolRx™ granted U.S. FDA Orphan Drug Designation for the treatment of pericarditis,
which includes recurrent pericarditis

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×